Domain, Rusnano invest in ReVision

Print 30 July 2013
BioCentury

Domain Associates and Rusnano, the state-funded $10 billion Russian fund, made their fifth investment under a 2012 investment partnership in Domain portfolio company ReVision Optics Inc. (Lake Forest, Calif.).

The ophthalmic device company raised $55 million in an undisclosed equity round from existing investors Canaan Partners; ProQuest Investments; InterWest Partner; and Domain, as well as new investors Rusnano and the Johnson & Johnson Development Corp. venture arm of Johnson & Johnson (NYSE:JNJ).

ReVision's Raindrop microscopic hydrogel inlay is in Phase III testing to treat presbyopia, the gradual loss of the eyes' ability to focus actively on nearby objects. The company markets the product in Europe and some Asian countries. As part of the financing, ReVision partnered with NovaMedica (Moscow, Russia), a JV between Domain and Rusnano, to commercialize Raindrop in the Commonwealth of Independent States (CIS). 

Source

Return